GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology AS (OSTO:SCOL) » Definitions » Institutional Ownership

Scandion Oncology AS (OSTO:SCOL) Institutional Ownership : 0.17% (As of May. 02, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology AS Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Scandion Oncology AS's institutional ownership is 0.17%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Scandion Oncology AS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Scandion Oncology AS's Float Percentage Of Total Shares Outstanding is 0.00%.


Scandion Oncology AS Institutional Ownership Historical Data

The historical data trend for Scandion Oncology AS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology AS Institutional Ownership Chart

Scandion Oncology AS Historical Data

The historical data trend for Scandion Oncology AS can be seen below:

2023-09-30 2023-10-31 2024-07-31 2024-08-31 2024-09-30 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 0.01 0.01 0.04 0.04 0.04 0.17 0.17 0.17 0.17 0.17

Scandion Oncology AS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Scandion Oncology AS Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100
Scandion Oncology AS is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options. The company's pipeline includes products like COROST for Colorectal Cancer, PANTAX for Pancreatic Cancer, 101 for other cancer indiction, 201 for Solid Tumors.

Scandion Oncology AS Headlines

No Headlines